市場調查報告書
商品編碼
1541226
2024-2032 年按類型、應用(心室內不同步、心室間不同步、房室不同步)、最終用戶和地區分類的心臟再同步治療市場報告Cardiac Resynchronization Therapy Market Report by Type, Application (Intraventricular Dyssynchrony, Interventricular Dyssynchrony, Atrioventricular Dyssynchrony), End User, and Region 2024-2032 |
2023年,全球心臟再同步治療(CRT)IMARC Group規模達57億美元。心臟衰竭盛行率的上升、政府和監管支持的增加、有利的報銷政策以及新興經濟體醫療基礎設施的擴張是推動市場的一些主要因素。
心臟再同步治療(CRT)是一種先進的醫療程序,用於治療某些患者的心臟衰竭症狀。這種治療涉及使用一種透過手術植入胸部的專用設備,稱為 CRT 設備,類似於起搏器。該裝置的工作原理是將電脈衝傳輸到心室,從而協調它們的收縮。這種同步可以提高心臟的效率,減輕經常伴隨心臟衰竭的疲勞和呼吸急促等症狀。對於患有中度至重度心臟衰竭且心臟內電紊亂證據的個體,通常會考慮 CRT 並結合最佳的藥物治療。 CRT 的實施標誌著一種有針對性的心臟衰竭治療方法,旨在提高患者的生活品質和整體功能能力。
醫療保健基礎設施的快速發展,特別是在新興經濟體,在擴大 CRT 設備的覆蓋範圍方面發揮著至關重要的作用,這將刺激預測期內的市場成長。隨著各國投資現代化醫療設施、培訓醫療保健專業人員和加強醫療保健系統,獲得 CRT 等專業治療的機會變得越來越普遍。再加上醫療旅遊業的興起,患者在以具有競爭力的成本提供先進醫療技術的國家尋求治療,正在推動市場成長。此外,不斷增加的公私夥伴關係正在促進政府和私人實體之間的合作,以資助和促進 CRT。透過教育活動和專業研討會提高患者意識也促進了 CRT 的理解和接受,加快了產品的採用率。此外,製造商之間在產品開發、行銷和分銷方面的策略合作正在支持市場成長。除此之外,提供具有成本效益的 CRT 解決方案的本地製造商的出現正在促進競爭並使治療更容易獲得,從而推動心臟再同步治療市場的成長。
心臟衰竭盛行率增加
全球心臟衰竭發生率的上升是推動心臟再同步治療(CRT)市場成長的關鍵因素。隨著心臟衰竭變得越來越普遍,特別是在人口老化以及肥胖和糖尿病發病率增加的地區,對 CRT 等有效治療方法的需求正在增加。 CRT 能夠改善特定心臟衰竭患者的症狀和整體生活品質,這凸顯了其重要性。各種公共衛生措施也強調心臟衰竭的早期發現和治療,進一步推動了對 CRT 的需求。這種慢性疾病的日益普及需要不斷改進治療解決方案,使 CRT 成為當代心臟衰竭管理策略不可或缺的一部分。
科技的快速進步
CRT 領域的技術創新和進步為全球市場的成長做出了重大貢獻。主要參與者加大研發 (R&D) 力度,不斷改進 CRT 設備,提升其功效、安全性和病患相容性。多點起搏和自適應演算法等創新正在實現更個人化和高效的治療,滿足心臟衰竭患者的多樣化需求。先進技術的整合也有助於與其他醫療系統和患者監測工具的無縫協調。技術的不斷發展將 CRT 的益處擴展到更廣泛的患者群體,同時確保該療法始終處於心臟衰竭治療的前沿。
有利的政府和監管支持
政府和監管支援在塑造 CRT 市場方面發揮著至關重要的作用。透過提供明確的監管途徑,政府正在促進新的和改進的 CRT 設備更快地獲得批准。許多國家也投資於研究計劃,並與產業參與者合作,以促進該領域的創新。此外,政府支持的衛生計劃和政策的重點是減輕心臟衰竭的負擔,因此支持 CRT 等治療方法。監管機構與加強心臟衰竭護理目標的這種一致表明了一種堅定的方法,這有助於促進成長、標準化實踐和確保 CRT 在各個醫療保健系統中的可及性。
The global cardiac resynchronization therapy (CRT) market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5.4% during 2024-2032. The rising prevalence of heart failure, increase in government and regulatory support, favorable reimbursement policies, and expansion of healthcare infrastructure in emerging economies are some of the major factors propelling the market.
Cardiac resynchronization therapy (CRT) is an advanced medical procedure used to treat heart failure symptoms in certain patients. This treatment involves the use of a specialized device that is surgically implanted in the chest, known as a CRT device, which is akin to a pacemaker. The device functions by transmitting electrical impulses to the chambers of the heart, thereby coordinating their contractions. This synchronization can enhance the heart's efficiency, alleviating symptoms such as fatigue and shortness of breath that often accompany heart failure. CRT is typically considered for individuals with moderate to severe heart failure who display evidence of electrical disarray within the heart, in conjunction with optimal medical therapy. The implementation of CRT signifies a targeted approach to heart failure management, aimed at improving the quality of life and overall functional capacity of patients.
Rapid healthcare infrastructure development, particularly in emerging economies, is playing a vital role in expanding the reach of CRT devices, which will stimulate market growth during the forecast period. As nations invest in modernizing medical facilities, training healthcare professionals, and strengthening healthcare systems, access to specialized treatments like CRT is becoming more widespread. This, coupled with a rise in medical tourism, where patients seek treatment in countries offering advanced healthcare technologies at competitive costs, is fueling the market growth. Furthermore, the increasing public-private partnerships are fostering collaborations between governments and private entities to finance and promote CRT. Enhanced patient awareness through educational campaigns and professional workshops is also facilitating the understanding and acceptance of CRT, accelerating the product adoption rate. In addition, strategic collaborations between manufacturers for product development, marketing, and distribution are supporting market growth. Besides this, the emergence of local manufacturers offering cost-effective CRT solutions is fostering competition and making therapy more accessible, thus propelling the growth of the cardiac resynchronization therapy market.
Increase in Prevalence of Heart Failure
The rising incidence of heart failure globally is a key factor driving the growth of the cardiac resynchronization therapy (CRT) market. As heart failure becomes more prevalent, particularly in aging populations and areas with increased rates of obesity and diabetes, the demand for effective treatments like CRT is escalating. The ability of CRT to improve symptoms and overall quality of life in selected patients with heart failure underscores its importance. Various public health initiatives are also emphasizing early detection and treatment of heart failure, further propelling the need for CRT. The growing prevalence of this chronic condition necessitates continuous advancement in therapeutic solutions, making CRT an integral part of contemporary heart failure management strategies.
Rapid Technological Advancements
Technological innovation and advancements in the field of CRT are contributing significantly to the growth of the global market. Increased research and development (R&D) efforts by key players are continuously refining CRT devices, enhancing their efficacy, safety, and patient compatibility. Innovations like multi-point pacing and adaptive algorithms are enabling more personalized and efficient therapies, catering to the diverse needs of heart failure patients. The integration of sophisticated technologies also facilitates seamless coordination with other medical systems and patient monitoring tools. This constant evolution in technology is extending the benefits of CRT to a wider patient demographic while ensuring that the therapy remains at the forefront of heart failure treatment.
Favorable Government and Regulatory Support
Government and regulatory support play a crucial role in shaping the CRT market. By providing clear regulatory pathways, governments are facilitating faster approvals of new and improved CRT devices. Many countries are also investing in research initiatives and collaborating with industry players to foster innovation in the field. Moreover, government-backed health programs and policies are focusing on reducing the burden of heart failure and are thus endorsing treatments like CRT. This alignment of regulatory bodies with the objective of enhancing heart failure care demonstrates a committed approach, which is instrumental in fostering growth, standardizing practices, and ensuring the accessibility of CRT across various healthcare systems.
IMARC Group provides an analysis of the key trends in each segment of the global cardiac resynchronization therapy (CRT) market report, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, application, and end user.
CRT-Defibrillator
CRT-Pacemaker
CRT-Defibrillator represents the most popular type
The report has provided a detailed breakup and analysis of the market based on the type. This includes CRT-Defibrillator and CRT-Pacemaker. According to the report, CRT-Defibrillator represented the largest segment.
The CRT-Defibrillator (CRT-D) offers dual functionality in treating heart failure patients. Unlike standard CRT devices, CRT-D combines the features of cardiac resynchronization with defibrillation capabilities. This integrated approach enables the device to synchronize the heart's chambers, improving its efficiency, as well as to detect and correct life-threatening arrhythmias. By delivering a shock to the heart when it detects irregular rhythms, the CRT-D acts as a safeguard, adding an extra layer of protection for patients at high risk of sudden cardiac arrest. The all-encompassing nature of CRT-D extends its applicability, offering a comprehensive solution for managing both the chronic symptoms of heart failure and acute, critical arrhythmias. Additionally, improvements in device miniaturization, battery life, and programmability have contributed to its popularity. This consolidation of functions into one device, providing multifaceted care, has made CRT-D a preferred option, thus fueling the segment growth.
Intraventricular Dyssynchrony
Interventricular (V-V) Dyssynchrony
Atrioventricular (A-V) Dyssynchrony
Intraventricular Dyssynchrony dominates the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes intraventricular dyssynchrony, interventricular (V-V) dyssynchrony, and atrioventricular (A-V) dyssynchrony. According to the report, intraventricular dyssynchrony represented the largest segment.
Intraventricular dyssynchrony refers to the uncoordinated contraction of the heart's ventricles, leading to inefficient pumping and worsening heart failure symptoms. This specific form of dyssynchrony has been identified in a significant number of heart failure patients, making it a primary target for CRT. The use of CRT in managing intraventricular dyssynchrony is well-established, offering marked improvements in both symptoms and overall cardiac function. The precise targeting and correction of this dyssynchrony through CRT enables the heart to pump more efficiently, enhancing the patient's quality of life and reducing hospitalization rates. Research studies and clinical trials have further supported the effectiveness of CRT in this application, solidifying its position as a standard treatment. The pervasive presence of intraventricular dyssynchrony among heart failure patients and the proven success of CRT in addressing this condition are fueling the segment growth.
Hospitals
Cardiac Centers
Ambulatory Surgery Centers
Others
Hospitals hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, cardiac centers, ambulatory surgery centers, and others. According to the report, hospitals accounted for the largest market share.
Hospitals are often the primary setting for the diagnosis and treatment of heart failure, including the implantation and management of CRT devices. The complexity of CRT requires specialized equipment, skilled healthcare professionals, and coordinated post-procedure care, resources that hospitals are typically well-equipped to provide. Additionally, larger hospitals often have dedicated cardiac units with experts trained specifically in CRT, enabling comprehensive patient care from initial consultation through post-surgical monitoring. Many hospitals also engage in research and collaborate with device manufacturers, further aligning themselves with the advancements in CRT. The emphasis on integrated care pathways, coupled with the support of multi-disciplinary teams within the hospital setting, ensures that patients receive a seamless experience. This combination of resources, expertise, and patient-centric care is supporting the growth of the hospital segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region boasts a sophisticated healthcare infrastructure, emphasis on medical innovation, and robust regulatory support that have fostered a favorable environment for the adoption and advancement of CRT. North America is also home to a significant number of leading medical research institutions and device manufacturers, promoting continuous innovation in CRT technology. In addition, high awareness levels among healthcare professionals and the general population about heart failure and its treatment options contribute to the growing acceptance of CRT. Moreover, the prevalence of lifestyle-related diseases leading to heart failure is relatively high in this region, creating a substantial patient base. Favorable reimbursement policies and insurance coverage further ease the accessibility of CRT for patients. These factors, along with the increasing focus on patient-centered care, position North America as the largest regional market for cardiac resynchronization therapy (CRT).
The market is experiencing steady growth as key players are actively engaged in research and development (R&D), striving to innovate and enhance CRT technology. Collaborating with healthcare institutions, they are focused on creating devices with improved efficiency, patient compatibility, and integration with other healthcare systems. Expansion into emerging markets and strategic alliances with local distributors are also part of their growth strategies. Through acquisitions and partnerships, these industry leaders are consolidating their presence, sharing expertise, and fostering technological advancements. Investments in clinical trials to validate new applications and continued engagement with regulatory bodies for compliance ensure alignment with global healthcare needs. We also expect the market to witness new entrants, consolidation of portfolios, and a rise in strategic collaborations to drive healthy competition within the CRT domain.
Abbott Laboratories
Biotronik SE & Co. KG
Boston Scientific Corporation
LivaNova Plc
Medico S.p.A.
Medtronic Plc
Merit Medical Systems Inc.
MicroPort Scientific Corporation
In July 2023, Biotronik SE & Co. KG announced the approval of its next-generation portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy (CRT) devices by the U.S. Food and Drug Administration (FDA).
Abbott Laboratories has made recent developments in cardiac resynchronization therapy (CRT) by releasing updates to its implantable pacemakers and defibrillators, showcasing its commitment to continuously improve patient care.